For research use only. Not for therapeutic Use.
Avitinib maleate (CAT: I003312) is an orally available, irreversible inhibitor of the epidermal growth factor receptor (EGFR). It is also known as AC0010 or AC0010MA. Avitinib specifically targets EGFR mutants and has the potential to inhibit the growth of cancer cells. By forming a covalent bond, avitinib binds to the EGFR receptor, blocking its signaling pathways and interfering with cancer cell proliferation. This compound shows promise as an antineoplastic agent in the treatment of certain cancers driven by EGFR mutations.
| Catalog Number | I003312 |
| CAS Number | 1557268-88-8 (maleate) |
| Synonyms | Avitinib maleate; AC0010MA; AC-0010MA; AC 0010MA; AC0010; AC-0010; AC 0010.;N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide maleate |
| Molecular Formula | C30H30FN7O6 |
| Purity | ≥95% |
| Target | EGFR inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term or -20 °C for long term |
| IUPAC Name | (Z)-but-2-enedioic acid;N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide |
| InChI | InChI=1S/C26H26FN7O2.C4H4O4/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34;5-3(6)1-2-4(7)8/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32);1-2H,(H,5,6)(H,7,8)/b;2-1- |
| InChIKey | VRHPZWLHPIENFW-BTJKTKAUSA-N |
| SMILES | CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F.C(=CC(=O)O)C(=O)O |
| Reference | </br>1: Xu X. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Chin J Cancer. 2015 Jul 8;34(7):285-7. |
